Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

826.71 +1.09 (+0.13%)
Official Closing Price Updated: 7:00 PM EST, Dec 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,047,129
Open 827.68
Bid (Size) 825.01 (1)
Ask (Size) 832.78 (1)
Prev. Close 825.62
Today's Range 825.69 - 841.00
52wk Range 561.65 - 972.53
Shares Outstanding N/A
Dividend Yield 0.63%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Could Eli Lilly Beat Rivals in the Billion-Dollar Weight Loss Drug Market in 2025? Evidence Is Piling Up, and Here's What It Says.
Via The Motley Fool
Eli Lilly Stock Price Analysis – Earnings Miss And The Pullback Worth Watching
The company lowered its FY2024 guidance following Q3 earnings, citing supply chain challenges for top-selling drugs like Mounjaro and Zepbound and a one-time R&D expense from its $3.2 billion... 
Via Talk Markets
Topics Earnings Economy Stocks / Equities
Exposures Financial Supply Chain

Performance

YTD
+39.60%
+39.60%
1 Month
+6.48%
+6.48%
3 Month
-8.42%
-8.42%
6 Month
-2.74%
-2.74%
1 Year
+40.53%
+40.53%

More News

Read More
Eli Lilly Investments In Production Reach $23 Billion With Additional $3 Billion Expansion At US Facility
Via Benzinga
Alzheimer’s Disease Therapy Provides Patients With Hope
Via Brandpoint
Stock Market Hits Highs On Salesforce, Tech Earnings; Bitcoin Tops $100,000, Briefly: Weekly Review
Via Investor's Business Daily
Are you living with eczema? It's time to get the care you deserve
Via Brandpoint
Billionaire Izzy Englander Is Buying This Obesity Drug Stock That Could Soar Nearly 20%, According to Wall Street
Via The Motley Fool
How Much Did Americans Overspend On Weight Loss Medications in 2024? GoodRx Reveals
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
2 Telehealth Stocks That Could Gain from Trump’s New FDA Pick
Via MarketBeat
Topics Government Lawsuit
Exposures Financial Legal Political
Decoding Eli Lilly's Options Activity: What's the Big Picture?
Via Benzinga
The Weight-Loss Battle That Could Rattle Eli Lilly's $100 Billion Market
Via Investor's Business Daily
This Healthcare Stock Is a Favorite of Billionaires. But Is It a Buy?
Via The Motley Fool
Lilly Tops Nordisk In Weight Loss Battle
Via Talk Markets
Topics Stocks / Equities
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Stock Of The Day: Where Will The Eli Lilly Rally End?
Via Benzinga
Eli Lilly Stock Hits 3-Week High, Boosts Retail Mood On Zepbound’s Edge Over Wegovy In Weight-Loss Trial Showdown
Via Stocktwits
Eli Lilly's Zepbound Vs. Novo Nordisk's Wegovy - Which Shows Greater Weight Loss?
Via Benzinga
Jim Cramer: This Energy Stock Is A 'Winner,' But Navitas Semiconductor Is 'Losing A Lot Of Money'
Via Benzinga
Eli Lilly's Zepbound Beats Novo Nordisk's Wegovy In Head-To-Head Weight-Loss Trial
Via Investor's Business Daily
Eli Lilly Just Got a Bundle of Good News: Time to Buy?
Via The Motley Fool
Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo's Dominance
Via Benzinga
Want To Bet On Ozempic, Wegovy Success? Defiance Introduces Leveraged ETF To Capture Novo Nordisk Momentum
Via Benzinga
Topics ETFs
Eli Lilly Gap
Via Talk Markets
Topics Stocks / Equities
It’s Been A Tough Month For Healthcare Stocks
Via Talk Markets
Topics ETFs Stocks / Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.